Trial Profile

A Prospective Evaluation in a Non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS ElementTM Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Jun 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary)
Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
Focus Registrational; Therapeutic Use
Acronyms PERSEUS-SV
Sponsors Boston Scientific Corporation

31 Mar 2014 Status changed from active, no longer recruiting to completed as reported at the 63rd Annual Scientific Session of the American College of Cardiology.
31 Mar 2014 Final long-term 4 and 5 year results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
11 Feb 2013 Planned end date changed from 1 Sep 2013 to 1 May 2014 as reported by ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com